Highlight
– MEDI6570, an antibody antagonist of LOX‑1, produced dose-dependent reductions in soluble LOX‑1 (sLOX‑1) and lowered IL‑6 at higher doses in patients with recent MI and elevated hsCRP.
– The randomized phase 2 GOLDILOX‑TIMI 69 trial (n=423) found no effect of MEDI6570 on the primary imaging endpoint — change in noncalcified plaque volume in the most diseased coronary segment (NCPVMD) — or on global noncalcified or low‑attenuation plaque volume.
